Noelle C. Dubiansky

Noelle Dubiansky is a partner in the firm’s Technology and Life Sciences groups, where she serves as a strategic advisor to innovative companies across the biotechnology, pharmaceutical, medical device, and broader life sciences sectors. She is also a leader of the firm’s Business Law department in Washington D.C.,  and currently serves as the Hiring Partner in Washington D.C.

With deep expertise in intellectual property and commercial transactions, Noelle helps clients navigate high-stakes deals that fuel scientific advancement and business growth. She advises both private and public companies on a broad range of complex matters—including strategic partnerships, cross-border transactions, licensing, technology acquisitions, research and development collaborations, clinical trial arrangements, contract services, distribution, and manufacturing agreements. She also counsels clients through financings, IPOs, spin-outs, and M&A transactions, providing practical guidance on IP rights and operational risk.

Clients appreciate Noelle’s collaborative, solutions-driven approach to negotiations, which fosters alignment and trust while paving the way for lasting partnerships—often sidestepping the adversarial tone common in commercial dealmaking.

Prior to joining Goodwin, Noelle was an associate in the Life Sciences practice group at Cooley LLP and previously, in the FDA group at Hyman, Phelps & McNamara.

A selection of her recent representations includes:

• Septerna in its global collaboration with Novo Nordisk to develop oral small-molecule therapies targeting GPCRs for obesity and cardiometabolic diseases, a deal valued at up to $2.2 billion
• GRIN Therapeutics in its $570 million collaboration with Angelini Pharma to develop and commercialize radiprodil outside North America
• Orionis Biosciences in its multi-year collaboration with Genentech to develop monovalent glue medicines, a deal valued at over $2 billion
• Isomorphic Labs in its strategic AI-driven drug discovery collaboration with Novartis, initially valued at up to $1.2 billion and later expanded to include additional research programs
• Eidos Therapeutics, a BridgeBio company, in its $310 million license agreement with Bayer to commercialize acoramidis for transthyretin amyloidosis in Europe
• BridgeBio Pharma and QED Therapeutics in their $100 million exclusive license agreement with Kyowa Kirin to develop and commercialize infigratinib for skeletal dysplasias in Japan
• Vesalius Therapeutics in its multi-target strategic alliance with GSK to develop novel treatments for Parkinson’s disease and another neurodegenerative condition, a deal involving $80 million upfront and up to $570 million in potential milestones and royalties
• BridgeBio Pharma in its exclusive license agreement with Bristol Myers Squibb to develop and commercialize BBP-398, a SHP2 inhibitor for oncology, in a deal valued at up to $905 million
• Blueprint Medicines in its strategic collaboration with Proteovant Therapeutics to develop targeted protein degrader therapies, a deal valued up to $650 million
• BridgeBio Pharma in its strategic collaboration with Helsinn Group to co-develop and co-commercialize a novel GPX4 inhibitor for multiple cancer types
• Arvinas in its $1+ billion global collaboration with Pfizer to co-develop and co-commercialize ARV-471 for breast cancer
• QED Therapeutics in its $2.45 billion global collaboration with Helsinn Group to co-develop and commercialize infigratinib for oncology indications
• Cullinan Pearl, a Cullinan Oncology company, in its strategic collaboration and license agreement with Zai Lab for its EGFR inhibitor, CLN-081, for rights in Greater China.
• BridgeBio Pharma, Inc. in its joint venture with Maze Therapeutics to advance precision medicine to treat cardiovascular disease.
• Lacerta in its research, collaboration and licensing agreement with UCB Biopharma SRL (“UCB”) pursuant to which the parties will collaborate on developing novel gene therapies focused on a central nervous system disease with a high unmet need.
• insitro in its five-year, discovery collaboration with Bristol Myers Squibb focused on the discovery and development of novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) for up to $2.1 billion.
• BridgeBio Pharma, Inc. and its affiliates Navire and QED on collaboration agreements with LianBio to expand BridgeBio’s global reach into China, the second-largest pharmaceutical market in the world, for up to $531.5 million.
• Blueprint Medicines Corporation on its global collaboration agreement with F. Hoffmann-La Roche LTD and Genentech, Inc. for the development and commercialization of pralsetinib, an investigational once-daily oral precision therapy for the treatment of people with cancer driven by oncogenic RET alterations, for an upfront payment of $775 million.
• Yumanity Therapeutics in its strategic research collaboration and license agreement with Merck focused on accelerating the development of new treatments for neurodegenerative diseases for $500 million.
• Corvidia Therapeutics in its acquisition by Novo Nordisk A/S for $725 million up front and up to $2 billion.
• Orionis Biosciences on its major drug discovery collaboration with Novartis, to discover and design novel small molecule therapeutics, such as protein degraders, across various therapeutic areas, by broadly leveraging Orionis’ Allo-Glue™ technology platform.
• Cerevance in its research collaboration with Takeda to identify novel target proteins for certain GI disorders, for a deal value of over $170 million on a per target basis. 
• Blackstone Life Sciences in its joint investment alongside Ferring Pharmaceuticals of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in late-stage development for patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).
• BridgeBio Pharma subsidiary Eidos Therapeutics in connection with a licensing agreement that grants Alexion an exclusive license to develop and commercialize AG10 in Japan.
• BridgeBio Pharma in its launch of its subsidiary, QED Therapeutics, including its in-license of infigratinib from Novartis.
• Moderna Therapeutics in its license and collaboration with AstraZeneca to co-develop and co-commercialize a mRNA therapeutic candidate for the treatment of heart failure. 
• Warp Drive Bio in its strategic collaboration with Roche to discover and develop novel classes of antibiotics, for a deal value of up to $387 million.
• Lysosomal Therapeutics in its exclusive option arrangement with Allergan plc. 
• BlueRock Therapeutics, a next-generation regenerative medicine company, in its $225 million financing by Bayer and Versant Ventures and seminal in-licenses and alliances with Memorial Sloan Kettering, the Centre for Commercialization of Regenerative Medicine and University Health Networks.
• Cerevance in its launch by Lightstone Ventures and Takeda Pharmaceutical, which included $36 million in financing and seminal in-licenses with Takeda, and in connection with its $45 million Series B financing. 
• Brammer Bio in its acquisition of a biologics manufacturing facility from Biogen.
• Galapagos NV in connection with its $2 billion strategic collaboration with Gilead Sciences, Inc., including $300 million upfront and a $425 million equity investment. The deal was named the Top Biopharmaceutical Licensing Deal at the 2016 Allicense Deals of the Year. 
• Voyager Therapeutics in its $845 million collaboration and option agreement with Genzyme Corp. to develop and commercialize novel gene therapies for central nervous system disorders.

Noelle is a recommended key lawyer for Patents: licensing by The Legal 500.

Noelle has been recognized as a Washington D.C. Super Lawyers “Rising Star” by the Washington Lawyer magazine.